Highlights of FDA Oncology Approvals in 2023: Bispecific T-cell Engagers, Pediatric Indications, and Inclusive Drug Development
Authors:
- Joshua M. DonaldsonJDJoshua M. Donaldson
- Marjilla SeddiqMSMarjilla Seddiq
- Michael J. FuscoMFMichael J. Fusco
- Shyamli SinglaSSShyamli Singla
- Gulsum E. PamukGPGulsum E. Pamuk
- Rosa J. Lee-AlonzoRLRosa J. Lee-Alonzo
- Bronwyn D. MixterBMBronwyn D. Mixter
- Kirsten B. GoldbergKGKirsten B. Goldberg
- Laleh Amiri-KordestaniLALaleh Amiri-Kordestani
- R. Angelo de ClaroRCR. Angelo de Claro
- Nicole DreznerNDNicole Drezner
- Nicole J. GormleyNGNicole J. Gormley
- 12 December 2023
- journal article
- editorial
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 13 (12) , 2515-2524
Abstract
Summary: Cancer drug development remained robust in 2023. Highlights of U.S. drug approvals this year include new immunotherapies and targeted drug development in adult and pediatric patients as well as patients with rare diseases.Keywords
This publication has 5 references indexed in Scilit:
- Driving Diversity and Inclusion in Cancer Drug Development – Industry and Regulatory Perspectives, Current Practices, Opportunities, and ChallengesClinical Cancer Research, 2023
- Trends in the approval of cancer therapies by the FDA in the twenty-first centuryNature Reviews Drug Discovery, 2023
- Eligibility criteria and Enrollment of a Diverse Racial and Ethnic population in Multiple Myeloma Clinical TrialsBlood, 2023
- The Development of the Oncology Center of Excellence Patient-Friendly Language Glossary of Oncology Clinical Trial TermsThe Oncologist, 2023
- Patient-Reported Outcomes in Pediatric Cancer Registration Trials: A US Food and Drug Administration PerspectiveJNCI: Journal of the National Cancer Institute, 2021